Related Experiment Video
Updated: Sep 28, 2026
Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
Published on: June 11, 2017
Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo
J D Ahn1, R Morishita, Y Kaneda
1Department of Microbiology, Kyungpook National University, Taegu, Korea.
Abstract:
The transcription factor, E2F, plays a critical role in the trans-activation of several genes involved in cell cycle regulation. Previous studies showed that the transfection of cis element double-stranded decoy oligodeoxynucleotides (ODNs) corresponding to E2F binding sites inhibited the proliferation of vascular smooth muscle cells (VSMCs) and neointimal hyperplasia in injured vessels. We have developed a novel E2F decoy ODN with a circular dumbbell structure (CD-E2F) and compared its effects with those of the conventional phosphorothioated E2F decoy (PS-E2F) ODN. CD-E2F ODN was more stable than PS-E2F ODN, largely preserving its structural integrity after incubation in the presence of nucleases and sera. Moreover, CD-E2F ODN inhibited high glucose- and serum-induced transcriptional expression of cell cycle regulatory genes more strongly than PS-E2F ODN. Transfection of CD-E2F ODN resulted in more effective inhibition of VSMC proliferation in vitro and neointimal formation in vivo, compared with PS-E2F ODN. An approximately 40-50% lower dose of CD-E2F ODN than PS-E2F ODN was sufficient to attain similar effects. In conclusion, our results indicate that CD-E2F ODN may be a valuable tool in gene therapy protocols for inhibiting VSMC proliferation and studying transcriptional regulation.
Insights
A novel circular dumbbell E2F decoy oligodeoxynucleotide (CD-E2F ODN) demonstrates superior stability and efficacy. This new decoy ODN effectively inhibits vascular smooth muscle cell proliferation and neointimal formation, offering a promising gene therapy tool.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Gene Therapy
Background:
- The transcription factor E2F is crucial for cell cycle gene regulation.
- E2F decoy oligodeoxynucleotides (ODNs) have shown potential in inhibiting vascular smooth muscle cell (VSMC) proliferation and neointimal hyperplasia.
- Conventional phosphorothioated E2F decoy ODNs (PS-E2F ODN) face limitations in stability and efficacy.
Purpose of the Study:
- To develop and evaluate a novel circular dumbbell E2F decoy ODN (CD-E2F ODN).
- To compare the stability and inhibitory effects of CD-E2F ODN against conventional PS-E2F ODN.
- To assess the therapeutic potential of CD-E2F ODN in inhibiting VSMC proliferation and neointimal formation.
Main Methods:
- Development of a circular dumbbell E2F decoy ODN (CD-E2F ODN).
- Comparative analysis of structural stability of CD-E2F ODN and PS-E2F ODN in the presence of nucleases and sera.
- In vitro and in vivo experiments to assess the inhibition of VSMC proliferation and neointimal formation.
- Evaluation of transcriptional expression of cell cycle regulatory genes.
Main Results:
- CD-E2F ODN exhibited significantly enhanced stability compared to PS-E2F ODN.
- CD-E2F ODN demonstrated stronger inhibition of high glucose- and serum-induced gene expression.
- Transfection with CD-E2F ODN resulted in more effective inhibition of VSMC proliferation in vitro and neointimal formation in vivo.
- A 40-50% lower dose of CD-E2F ODN achieved similar or superior effects compared to PS-E2F ODN.
Conclusions:
- CD-E2F ODN represents a more stable and potent alternative to conventional E2F decoy ODNs.
- The findings suggest CD-E2F ODN is a valuable tool for gene therapy targeting VSMC proliferation.
- This novel ODN holds promise for studying transcriptional regulation and treating vascular proliferative diseases.
